Ionis Pharmaceuticals, the largest holding company in BB Biotech’s portfolio, has been in the news. The American biotech company today presented the results of a phase 2b study of fesomersene. The drug candidate is being developed as a factor XI production-reducing drug to prevent thrombosis – previously in collaboration with license partner Bayer, which also conducted the study. The study involved , hemodialysis patients with end-stage renal disease. „In the study, Fesomersen achieved its primary endpoint of major bleeding and clinically significant non-major bleeding (CRNM) over a 2 -week treatment period,” reports Ionis Pharma. Other learning objectives were also met. Fesomersen also demonstrated favorable safety and tolerability over a 8-week treatment period, according to the biotech company.